Is ATYR stock safe? | Glauxie AI

Q: Is ATYR stock safe?

aTyr Pharma, Inc. (ATYR) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Sanjay S. Shukla. aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is... Employees: 58.

Q: What are the risks of investing in ATYR?

Identify key risks of investing in ATYR — debt, competition, volatility, and sector headwinds.

Q: Is ATYR a good long-term investment?

Evaluate ATYR as a long-term investment using fundamental scores, growth metrics, and risk assessment.

Q: How much debt does ATYR have?

Review ATYR total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Is ATYR stock safe?

🦉

aTyr Pharma, Inc. (ATYR)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOSanjay S. Shukla

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis;...

Key Executives

Name	Title
Ashlee Dunston	Director of Investor Relations & Corporate Communications
Dalia R. Rayes	Head of Commercial, Global Efzofitimod Franchise
Danielle Campbell	Vice President of Human Resource
Jill Broadfoot	Chief Financial Officer
Leslie Nangle	Vice President of Research
Nancy E. Denyes Krueger	General Counsel & Corporate Secretary

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

ATYR Profile Financials

What are the risks of investing in ATYR? Is ATYR a good long-term investment? How much debt does ATYR have?